ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Unraveling the ferroptosis landscape in intervertebral disc degeneration through integrated bioinformatics and single-cell sequencing.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intervertebral disc degeneration (IVDD) is a major contributor to lumbar degenerative diseases and chronic low back pain, while the role of ferroptosis in its pathogenesis remains incompletely understood. In this study, we integrated transcriptomic and single-cell RNA sequencing analyses to systematically identify ferroptosis-related key gene networks and explore potential pharmacological interventions. Bioinformatics analysis identified seven core hub genes, including JUN, TGFB1, MAPK1, CDKN1A, DUSP1, TIMP1, and HSF1, which were mainly enriched in ErbB, HIF-1, FoxO, and MAPK signaling pathways. Single-cell analysis revealed 12 major cell subpopulations, among which inflammatory and chondrocyte-like nucleus pulposus (NP) cells were significantly enriched in degenerated discs. CytoTRACE trajectory inference indicated that regenerative and notochordal-like NP cells exhibited higher differentiation potential. The hub genes showed highly heterogeneous expression patterns across cell types, and the interaction strength between inflammatory NP cells and macrophages was markedly increased, suggesting their involvement in the degenerative microenvironment and ferroptosis regulation. Based on drug prediction and molecular docking, resveratrol demonstrated strong binding affinities with most core targets, with binding energies below - 5 kcal/mol. In vitro experiments further confirmed that resveratrol significantly improved IL-1β-induced reduction of NP cell viability as assessed by CCK-8 assays. RT-qPCR analysis showed that resveratrol effectively suppressed the overexpression of JUN, TGFB1, MAPK1, DUSP1, TIMP1, and HSF1, while upregulating the expression of CDKN1A, thereby exerting a protective effect. Collectively, this study systematically elucidates the ferroptosis-related molecular networks and their distribution across cellular subpopulations in IVDD, and demonstrates the potential of resveratrol as a candidate therapeutic agent, providing novel insights for targeted intervention strategies.
Indexed as
Identifiers
41288682What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.